Imagine if we could simply shut off the source of toxic proteins that lead to Alzheimer’s disease. Sounds like science fiction, right? But that’s exactly what Roche’s groundbreaking drug, nivegacetor, aims to do. Instead of just clearing the damage, this innovative treatment targets the root cause by modulating γ-secretase, an enzyme responsible for producing harmful amyloid-beta (Aβ) peptides. And this is the part most people miss: it’s not just about reducing plaque; it’s about preventing its formation in the first place.
At the recent CTAD conference in San Diego, Rosanna Tortelli from Hoffmann-La Roche unveiled exciting data from a Phase 1b study of nivegacetor in individuals carrying the PSEN1 E280A mutation—a genetic variant linked to early-onset Alzheimer’s in the Paisa kindred of Colombia. This mutation disrupts the normal processing of amyloid precursor protein (APP), leading to an overproduction of toxic Aβ42 peptides. But here’s where it gets controversial: nivegacetor successfully shifted APP processing toward shorter, less harmful Aβ peptides, even in these high-risk individuals. Could this be the breakthrough we’ve been waiting for?
Here’s the kicker: The drug didn’t just work in theory; it demonstrated consistent results in both plasma and cerebrospinal fluid (CSF), regardless of whether participants carried the mutation. This suggests that nivegacetor is effectively engaging its target and altering the course of amyloid production. But will it translate into long-term benefits for patients? That’s the million-dollar question.
In 2021, Roche initiated a Phase 1 trial in healthy volunteers, showing that nivegacetor could dramatically reduce pathogenic Aβ40 and Aβ42 while boosting the production of shorter, less harmful variants like Aβ37 and Aβ38. Unlike earlier γ-secretase inhibitors, which failed due to toxic side effects, nivegacetor leaves other substrates of the enzyme untouched—a critical advantage. These promising results propelled the drug into Phase 2 trials in 2024, making it the first and only γ-secretase modulator to reach this stage.
But here’s the real challenge: Will it work for those with autosomal-dominant Alzheimer’s mutations, like the Paisa cohort, where the enzyme itself is mutated? This group, hailing from a specific region in Colombia, typically develops memory issues in their 40s. Robert Alexander, a clinical trial investigator, emphasizes the urgency: ‘We need to understand how the drug affects these individuals, where the balance of amyloid fragments is already skewed.’
To tackle this, Tortelli and her team recruited 20 young adults from the Paisa lineage, 15 of whom carried the PSEN1 E280A mutation. Participants received escalating doses of nivegacetor for a week, and the results were striking. The drug produced a dose-dependent shift in Aβ processing, reducing longer peptides while increasing shorter ones—both in plasma and CSF. In carriers receiving the highest dose, Aβ42 levels plummeted by 72% in plasma and 53% in CSF, while Aβ37 and Aβ38 concentrations soared.
But here’s the debate: While nivegacetor shows promise, downstream biomarkers like phospho-tau217 and neurofilament light chain (NfL) remained unchanged in this short trial. Does this mean the drug isn’t potent enough, or is it simply too early to see these effects? Tortelli suggests the latter, noting that amyloid buildup is a slow process, and changes in biomarkers may take months to emerge.
Looking ahead, the focus is on early intervention. Since nivegacetor slows plaque accumulation, it may be most effective in individuals with low plaque levels at the start of treatment. This idea is being tested in an upcoming trial combining nivegacetor with donanemab, Lilly’s anti-amyloid antibody. Led by Alexander, the study will treat mutation carriers in Colombia with donanemab to reduce brain amyloid, followed by a factorial trial comparing nivegacetor, donanemab, their combination, and a placebo. The goal? To determine the best approach for maintaining low amyloid levels.
Here’s the question we can’t ignore: Could this combination therapy be the key to preventing Alzheimer’s in high-risk populations? And if so, what does it mean for the millions of people without genetic mutations but still at risk? Share your thoughts in the comments—this is a conversation we all need to be part of.
